Printer Friendly
The Free Library
4,658,636 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Aerscher owner ticked off at FDA validation desires.


Aerscher Diagnostics, Chestertown, MD, was cited for process validation See validate.

validation - The stage in the software life-cycle at the end of the development process where software is evaluated to ensure that it complies with the requirements.
 deficiencies in a May 18 letter following an April 21-23 audit of the firm's IVD (Interactive VideoDisc) See interactive video.  production by the Baltimore District Office.

FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 found the firm's April 25 response deficient de·fi·cient
adj.
1. Lacking an essential quality or element.

2. Inadequate in amount or degree; insufficient.



deficient

a state of being in deficit.
 because there was no listing of specific actions that would be taken to correct the deficiencies and estimated time to complete the corrections.

Company owner Dr. Robert Schreiber, M.D., owner, expressed frustration with the inspection process in an Aug. 13 interview. "They said I have to do validation," he said. "This is purely a one-man operation. I do everything. For me to write down validation procedures makes no sense. I'd be writing down procedures for myself."

"I'm not even small," the doctor lamented la·ment·ed  
adj.
Mourned for: our late lamented president.



la·mented·ly adv.
. "I'm a minuscule minuscule

Lowercase letters in calligraphy, in contrast to majuscule, or uppercase letters. Unlike majuscules, minuscules are not fully contained between two real or hypothetical lines; their stems can go above or below the line.
 company."

Schreiber said neither FDA nor 10 mechanical consultants he has hired understood his device. "They [FDA] would ask 'how do you know the temperature is working?' I would tell them," he recalled.

Schreiber also said FDA did not say how many runs to do for validation. "They just say get this book. They told me publications to buy. They said: 'you can get this through the Internet', but it doesn't apply to your particular problem. It doesn't say anything specific."

Schreiber said the big problem the agency had was with his documentation. "I do document things, but I would have to write a book to tell how this machine works. I could write a summary but it doesn't tell anything. I'm changing the machinery a lot. I can't write down everything I do. It's an enormous amount of paperwork to get to where I've gotten."

The physician also said he had to hire a consultant to reply to the 483, primarily to "interpret the jargon jargon, pejorative term applied to speech or writing that is considered meaningless, unintelligible, or ugly. In one sense the term is applied to the special language of a profession, which may be unnecessarily complicated, e.g., "medical jargon. " in the agency's observations.

Schreiber lamented that he felt unable to communicate freely with the investigators. "It would be nice to have free communication with them without your words being used against you," he added. "FDA generally is not helpful in guiding you at all. They say there has to be someone trained in statistics, some trained in quality standards. They're applying the same standards to me as big companies."
COPYRIGHT 1999 Washington Information Source, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Food and Drug Administration
Publication:Validation Times
Article Type:Brief Article
Geographic Code:1USA
Date:Aug 1, 1999
Words:361
Previous Article:Warning Letter Analysis.
Next Article:Andersen bag-sealing, sterilization slapped.(Brief Article)
Topics:



Related Articles
Manufacturers may promote off-label uses for drugs.
Nassmith answers citations by recalling its OTC drugs.(Brief Article)
Nassmith exits OTC market after validation citations.(over the counter drugs)(Brief Article)
Process, cleaning validation, stability hit OTC drug maker.(over the counter)(Brief Article)
Inspections seen replacing ELA, other CBER rules.(establishment licensing applications)(Brief Article)
ICH panels to review solvents, specifications : Product quality guidelines reach Step 1.(Brief Article)
Major inspection looks at Biocraft dosage forms, BPCs.(Brief Article)
Firms should move to process analytical technology, top CDER official says.(Center for Drug Evaluation and Research's Jane Axelrad)(Brief Article)
Food and Drug Administration may re-issue some revoked Part 11 guidance; validation guide still has merit.
An overview of drug development in the United States and current challenges.(Featured CME Topic)

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles